Loading
A phase 2/3 trial in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients is a phase 2/3, randomised interventional study registered as NCT06908772 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 390 participants, started 2025-04-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Glumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets Placebo. Conditions listed: Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression. Primary outcome: Phase 2：ORR as assessed by IRC. Lung eligibility wording from the registry: "Patients with NSCLC who have unresectable locally advanced or metastatic disease; 4". No results are recorded here; the registry entry is the source.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.